Sandu Pharmaceuticals board meet July 11, 2026 for new MD

Why this board meeting matters

Sandu Pharmaceuticals Limited has scheduled a board meeting on July 11, 2026, as the company begins a formal transition in top leadership after the demise of its Managing Director and Promoter, Shri Umesh B. Sandu. The meeting is expected to record the board’s note of his passing and acknowledge his contributions. It will then consider the appointment of a new Managing Director, along with changes in board committee structures. The company has also announced a trading window closure for directors and designated employees, aligning with insider trading compliance norms around results-related information.

This set of agenda items is closely tracked by investors because it covers continuity of management, governance processes, and the company’s near-term disclosure calendar for quarterly results.

Demise of Managing Director and promoter

Sandu Pharmaceuticals disclosed that Shri Umesh Sandu passed away on June 19, 2026. The company described the development as an irreparable loss and stated that he ceased to be a member of the Audit Committee and Stakeholders Relationship Committee following his demise. The disclosure was made to the stock exchange under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company also shared his status and shareholding at the time of his demise. Shri Umesh Sandu (DIN: 01132141) was serving as Managing Director and was classified as a promoter, holding 13,88,693 shares.

Agenda for July 11, 2026: leadership and governance

According to the company’s communication, the board meeting on July 11, 2026 will have multiple governance-related items:

• Recording the demise of Shri Umesh B. Sandu and acknowledging his contributions.
• Considering the appointment of a new Managing Director.
• Reconstituting board committees.
• Appointment of an additional independent director.

The company indicated that the Managing Director appointment will be subject to shareholder and regulatory approvals.

Key meeting details: time and venue

The meeting has been scheduled for the afternoon and will be held at the company’s corporate office in Mumbai.

Trading window closure linked to Q1FY27 results

Sandu Pharmaceuticals has closed its trading window for directors and designated employees starting July 1, 2026. The window will reopen 48 hours after the company announces financial results for the quarter ended June 30, 2026.

This is a standard compliance step used by listed companies to reduce the risk of insider trading around unpublished price sensitive information, particularly during the period leading up to quarterly results.

Board and committee changes: what is on the table

The company has explicitly included committee reconstitution as part of the July 11 agenda, along with the proposed appointment of an additional independent director. It also noted that Shri Umesh Sandu ceased to be a member of the Audit Committee and Stakeholders Relationship Committee after his demise. Together, these points indicate that committee compositions may need to be updated to maintain required governance structures.

Separately, the company’s available board information reflects a mix of non-executive and independent directors, including a chairman identified as an independent director. The average board tenure referenced in the provided data is 2.7 years.

Shareholding and management snapshot mentioned in disclosures

The company provided a specific shareholding figure for Shri Umesh Sandu at the time of his demise: 13,88,693 shares. Other board-related data in the provided material also lists promoter family ownership percentages and compensation figures, including that Umesh Sandu was shown as MD and Executive Director with compensation of ₹10.28 million and ownership of 14.37%.

Investors typically watch such disclosures during a succession event because promoter shareholding, board composition, and key managerial roles can influence how quickly a company stabilises leadership and internal decision-making.

Stock snapshot as of July 10, 2026

Market participants also track price action around key corporate updates. As per the information provided:

• Sandu Pharmaceuticals traded at 41.00, up 0.43 or 1.06%.
• Day range was 40.67 to 41.47.
• 1-year returns were -18.57%.
• The timestamp shown was “As on 10 Jul, 2026 | 04:01”.

This data offers context on recent performance but does not by itself explain the reasons behind the move.

Regulatory context: Regulation 30 disclosures

The company’s communication references compliance with Regulation 30 of SEBI LODR, 2015, which is used for timely disclosure of material events. In this case, the material event was the demise of a Managing Director and promoter and the resulting change in committee membership.

The July 11 board meeting agenda, which includes appointment of a new Managing Director subject to approvals, also fits within the framework of exchange disclosures that investors expect during senior management transitions.

What investors may watch next

The immediate next milestones identified in the disclosure are procedural and time-bound. First is the board meeting on July 11, 2026 to consider leadership succession, committee reconstitution, and the appointment of an additional independent director. Second is the pending announcement of financial results for the quarter ended June 30, 2026, after which the trading window will reopen 48 hours later.

Any further clarity on who is proposed as Managing Director and how committees are reconstituted is expected only through formal company announcements after the meeting.

Conclusion

Sandu Pharmaceuticals has placed leadership succession and governance restructuring on the agenda for its July 11, 2026 board meeting following the demise of Managing Director and promoter Shri Umesh B. Sandu on June 19, 2026. Alongside the proposed Managing Director appointment, the company plans to rework committee compositions and consider an additional independent director. The trading window remains closed from July 1, 2026 and will reopen 48 hours after the Q1FY27 results are announced, keeping the focus on the company’s next set of disclosures.